Sponsored by
News Support offered for Midlands HealthTech researchers
SPARK The Midlands, a network offering support to researchers developing innovations for unmet clinical needs in the region, based at Aston University, has launched a call for applications for its third cohort. The network, which launched in 2024, aims
to bridge the gap between medical research discoveries of novel therapeutics, medical devices and diagnostics, and real-world clinical use. Any Midlands-based researchers developing a therapeutic, medical device or diagnostic for an unmet clinical need that would eventually need regulatory approval to enter market, is eligible to apply. For the first time, SPARK The Midlands is now also open to researchers based in the East Midlands, having previously only been open to researchers in the West Midlands. For successful applicants, the first six months
of the SPARK programme consists of six one-to- one meetings on completing a target product profile, building a five-year project plan, creating a compelling narrative, pitching and effective decks, constructing a data room and addressing risk pillars. Following this onboarding period, cohort members receive two years of bespoke support with the aim of getting the funding in place to achieve the five-year plan devised during the second team meeting. There are monthly cohort meetings to encourage members to share knowledge and expertise, tackle challenges side by side and inspire each other to go further. They also gain access to the SPARK Global network. Since its launch, SPARK The Midlands has
a portable, handheld tool designed for efficient and versatile anterior eye examination. Additionally, Crism Therapeutics, a University
of Birmingham spinout focused on the localised and sustained delivery of chemotherapy drugs, has gained regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to go to clinical trial in 2026 with a drug delivery system called ChemoSeed to treat glioblastoma, a type of brain cancer. Matt Vassey, newly appointed as SPARK East Midlands director, said: “The Midlands is home to extraordinary
achieved some notable successes, including raising more than £15m in follow-on funding. Three new spinouts have been launched, two
from Aston University – Dr. Jill Johnson’s company Fibraxis, which is developing a new, inhalable daily medication that halts and reverses the structural lung damage that occurs in asthma, and Dr. Vivian (Zhuo) Wang’s Kleis Therapeutics, which is developing targeted molecules called transglutaminase 2 inhibitors to treat fibrotic lung diseases. A third, Solute Guard Therapeutics, which is developing treatments for autoimmune conditions such as rheumatoid arthritis and psoriatic arthritis, is based at the University of Birmingham. One new medical device, Aston Vision Sciences’ (AVS) Lumio device, has entered the market. This is
research talent, and with SPARK now open to the East Midlands we have a fantastic opportunity to turn more brilliant ideas into breakthroughs that change lives. As we launch our third cohort and extend support across the East Midlands, we are excited to connect with researchers and clinicians to provide tailored expertise to accelerate the translation of innovative therapies, devices and diagnostics into practice. I am excited to work alongside our new cohort and help them take bold steps towards transforming patient care.” SPARK The Midlands is the first UK branch of
Stanford University’s prestigious global SPARK programme. It comes as a result of Aston University’s active involvement in the delivery of the West Midlands Health Tech Innovation Accelerator (WMHTIA) – a government-funded project aimed at helping companies drive their innovations towards market success. Visit
https://tinyurl.com/284b8s99 to submit an application.
Decontamination Training
We deliver NHS aligned hands on practical courses to build confidence, competence & compliance in decontamination
Introduction to decontamination operations (1Day) Get to grips with SSD roles & equipment essentials
Decontamination lead – role & responsibilities (4 Days) Authorised Person (Decontamination) refresher (3 Days)
Step up with the skills to lead & stay compliant +44 (0)1454 262777
Refresh your AP(D) knowledge - Stay current, Stay compliant
training@eastwoodpark.co.uk
November 2025 I
www.clinicalservicesjournal.com 13
e
S
r
c
o
a
n
t
h
e
Q
R
c
o
d
e
t
o
f
i
n
d
o
u
t
m
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
